<DOC>
	<DOCNO>NCT01636141</DOCNO>
	<brief_summary>The purpose study determine OLT1177 Gel safe tolerate give single dose multidose define area one knee healthy subject .</brief_summary>
	<brief_title>Phase 1 Safety Study Single Multi-Dose Topically Applied OLT1177 Gel Healthy Subjects</brief_title>
	<detailed_description>OLT1177 Gel develop topical treatment pain inflammation emanate musculoskeletal certain skin inflammatory condition . This Phase 1 study evaluate safety tolerability OLT1177 Gel healthy subject give single-dose multi-dose application . The study conduct two part , Part A Part B . In Part A , approximately 18 healthy subject 3 dose escalate cohort randomize receive single dose investigational drug ( 5 subject OLT1177 Gel 1 subject placebo gel ) . Upon completion Part A , new subject population approximately 18 subject 3 dose escalate cohort randomize Part B study . Subjects receive total 8 dos 3 consecutive day give 6 hour apart awake day follow 30 day safety assessment .</detailed_description>
	<criteria>Healthy men woman 18 60 year age Women childbearing potential must negative urine pregnancy test within 3 day study enrollment must agree use highly effective form contraception Subjects must good health determine Investigator base medical history , ECG , physical examination safety laboratory test Ability provide write informed consent prior initiation studyrelated procedure , ability , opinion Investigator , comply requirement study Subjects know hypersensitivity investigational drug Subjects pregnant lactate Participation investigational drug device study receipt investigational drug device within immediate 30 day prior start study Concurrent recent use analgesic , steroid , allergy medication , H2 blocker within 48 hour start study Subjects prior knee injury surgery within last 5 year Subjects active infection fever ≥ 38°C within 3 day start study Subjects history , know positive , HIV , hepatitis B C Subjects uncontrolled hypertension define systolic blood pressure ( SBP ) &gt; 150 mm/Hg , diastolic blood pressure ( DBP ) &gt; 100 mm/Hg Subjects wound skin irritation skin condition , e.g. , psoriasis treatment area Subjects take prescription medication exception oral systemic contraceptive Subjects systemic disease Subjects history anaphylactic reaction systemic topical compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Randomized</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Topical</keyword>
	<keyword>OLT1177</keyword>
	<keyword>Olatec</keyword>
	<keyword>Pain</keyword>
	<keyword>Inflammation</keyword>
</DOC>